A small molecular agent YL529 inhibits VEGF-D-induced lymphangiogenesis and metastasis in preclinical tumor models in addition to its known antitumor activities

Table 1 Pharmacokinetic parameters of YL529 after oral administration with single dose of 150 mg/kg in mice

Data were expressed as the mean ± SD compared with vehicle. SPSS (SPSS, IL) software was used for statistical analysis (n = 3; *p < 0.05)

ISSN: 1471-2407